The Mystique of the Phantom "Gay Gene"
By Philip L. Bereano,
Seattle Times
| 02. 26. 1996
"If homosexuality is inherited, shouldn't it have died
out by now?"- two women talking in a New Yorker cartoon.
Last October 10th the US Supreme Court heard arguments in the
case of Romer v Evans, concerning Amendment 2 to the Colorado
Constitution, adopted by referendum, which would bar all state
and local laws protecting homosexuals from discrimination. The
courts in Colorado had thrown out the Amendment by claiming
that it infringed on the "fundamental right to participate
equally in the political process" by "fencing out
an independently identifiable class of persons" without
showing that the amendment "support(ed) a compelling state
interest" and was "narrowly tailored to meet that
interest."
In the proceedings in the lower Colorado courts, one of the
witnesses was a Federal scientist, Dean Hamer, who testified
that homosexuality was a genetically caused, rather than a cultural
or chosen, behavior. He was put on the stand by gay rights activists
trying to utilize language of an earlier Supreme Court case
which suggested that government's ability to protect a group
of people from discrimination might somehow be linked to...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...